solution à diluer pour perfusion.
Sponsors
Centre Hospitalier Universitaire De Toulouse, Institut Paoli Calmettes, Hospices Civils De Lyon, Fondation Franc.Cancerologie Digestive
Conditions
Breast cancerCervical CancerResectable borderline pancreatic adenocarcinomaThe patients enrolled in IMMUNORARE will be adult patients with 5 rare cancers:
-Cohort 1: Peritoneal mesotheliomas (PM)
-Cohort 2: Gestational trophoblastic tumors (GTT)
-Cohort 3: B3 thymomas and thymic carcinomas (TET)
-Cohort 4: Anaplastic thyroid carcinomas (ATC)
-Cohort 5: GEP-NET & carcinoid tumors (GEP-NET/TCT/UP-NET)
Patients will have advanced/metastatic cancers found to be progressive/resistant after at least one previous line of standard systemic treatment.
Phase 2
PELICAN-IPC 2015-016 A prospective, multicentre, open-label, randomized, Phase II study of Pembrolizumab in combination with neo-adjuvant EC-Paclitaxel regimen in HER2-negative inflammatory Breast Cancer
Not yet recruitingCTIS2024-514899-41-00
Target: 72Updated: 2024-10-31
IMMUNORARE5 : A national platform of 5 academic phase II trials coordinated by Lyon university hospital to assess the safety and the efficacy of the IMMUNOtherapy with Domvanalimab + Zimberelimab combination in patients with advanced RARE cancers
SuspendedCTIS2024-517254-99-00
Start: 2025-09-16Target: 186Updated: 2026-01-07
PRODIGE 104 – NEOPREDICT
A multicenter phase II trial using transcriptomic signatures to personalize neoadjuvant chemotherapy for patients with resectable borderline pancreatic adenocarcinoma.
Not yet recruitingCTIS2024-519753-11-00
Target: 110Updated: 2025-10-17